Comments on: “In Vitro Safety Pharmacology Profiling of Topical α-Adrenergic Agonist Treatments for Erythema of Rosacea”
Crossref DOI link: https://doi.org/10.1007/s40268-018-0242-z
Published Online: 2018-08-04
Published Print: 2018-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Gil, Daniel
Text and Data Mining valid from 2018-08-04
Article History
First Online: 4 August 2018
Compliance with Ethical Standards
:
: No funding was received for the preparation of this letter.
: Daniel Gil, PhD, is an employee of Allergan plc, Irvine, CA, USA.